• Coronavirus in Hungary
  • Budapest
  • Hungary border control
  • HelloMagyar
EnglishFrenchGermanSpanish
EnglishFrenchGermanSpanish
COVID-19 vaccine trial by Moderna shows positive early resultsCOVID-19 vaccine trial by Moderna shows positive early resultsCOVID-19 vaccine trial by Moderna shows positive early resultsCOVID-19 vaccine trial by Moderna shows positive early results
  • Politics
  • Business
  • Society
  • Sport
  • Culture
  • Special Hungary
  • News To Go
  • World
  • Contact Us
  • About us
  • About us
  • Contact Us
  • Privacy Policy
✕
Breaking News
  • VIDEO, PHOTOS: Popular Budapest pool consumed in flames

Support us
Daily News Daily News · 18/05/2020
· World

COVID-19 vaccine trial by Moderna shows positive early results

coronavirus drugs/medications USA
coronavirus test vaccine

Illustration. Photo: MTI

U.S. biotech company Moderna on Monday announced positive interim clinical data of mRNA-1273, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.

The results came from Phase 1 study, led by the National Institute of Allergy and Infectious Diseases, which began in Seattle in March.

Moderna has vaccinated dozens of study participants and measured antibodies in eight of them.

All eight developed neutralizing antibodies to the virus at levels reaching or exceeding the levels seen in people who have naturally recovered from COVID-19, according to the company.

The vaccine mRNA-1273 was generally safe and well tolerated, with a safety profile consistent with that seen in prior Moderna infectious disease vaccine clinical studies, said the company.

These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 mcg, said Tal Zaks, chief medical officer at Moderna.

“When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials,” Zaks said.

The Moderna team continues to focus on moving as fast as safely possible to start the pivotal Phase 3 study in July, said Moderna CEO Stephane Bancel. “We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2.”

  • Hungary on course to produce favipiravir drug within months
hungary-coronavirus-hospital
Read alsoCoronavirus: Hungarian hospital successfully used Tocilizumab therapy to save the life of a doctor

Source: Xinhua

coronavirus drugs/medications USA
Share
Daily News
Daily News

Leave a Reply

Your email address will not be published. Required fields are marked *

SUPPORT US

Subscribe to our newsletter

Sign up to receive daily updates, news & stories about Hungary!

Select your location below or enter your country so we can deliver our morning newsletters to you in time.


Thank you!

You have successfully joined our subscriber list.


.

Latest news
  • S+P downgraded Hungary but the minister is positive about getting all EU money soon
  • VIDEO, PHOTOS: Popular Budapest pool consumed in flames
  • Mayor: Government treats Budapest unjust
  • World-famous Hungarian honey in danger!
  • Ukraine outraged: Orbán said behind closed doors that they would lose the war
  • Gyurcsány’s DK party envisions millions of protesters on Hungary’s streets
  • Significant price hikes expected at Lake Balaton this summer
  • Surprising: Hungarian minister named this country one of Hungary’s closest military allies

About us

Contact us

Copyright rules

© 2023 DailyNewsHungary. All rights reserved! | Server and development by Svigelj Levente E.V